Teva ecopipam shows durable tic reduction in Tourette trial

Teva Pharmaceuticals has presented a package of new clinical data for ecopipam, its investigational selective D1 receptor antagonist for paediatric Tourette syndrome, at the International Congress of Parkinson's Disease and Movement Disorders in Seoul. The data, drawn from post hoc analyses and an interim read of an ongoing open-label extension, reinforce the profile of a candidate already under FDA Priority Review.

The most eye-catching figure comes from an interim analysis of a 36-month open-label extension study covering 118 participants who had completed either the Phase 2b or Phase 3 D1AMOND trials. At 18 months, ecopipam produced a mean 45.6% reduction in Yale Global Tic Severity Scale Total Tic Score, and no new safety signals emerged. The most commonly reported adverse events were nasopharyngitis, upper respiratory tract infection, anxiety and insomnia.

Early onset of effect

A pooled post hoc analysis of 292 patients across the Phase 2b and Phase 3 programmes found that 69.8% of participants achieved a clinically meaningful tic improvement, defined as a YGTSS-TTS score reduction of at least 25%, within the first eight weeks of treatment. Somnolence and headache were the most common early adverse events. The speed of response matters clinically: rapid onset is often cited by neurologists as a factor in patient and carer adherence.

A further post hoc analysis examined outcomes in the 216-participant Phase 3 cohort, stratifying by the presence or absence of common co-occurring psychiatric conditions including ADHD, OCD, anxiety and depression. Tic severity reductions and tolerability profiles were consistent across both groups, an important practical finding given that comorbidities are the norm rather than the exception in Tourette syndrome.

Teva's chief medical officer Eric Hughes said that, if approved, ecopipam would be "the first new therapy for Tourette syndrome in more than 10 years and the first with a novel mechanism of action in more than 50 years." Donald Gilbert, a paediatric movement disorders specialist at Cincinnati Children's Hospital Medical Center, noted that many children with Tourette syndrome either go untreated or discontinue treatment within a year due to inadequate control or tolerability concerns.

Regulatory and competitive context

Ecopipam holds FDA Priority Review and Orphan Drug designation, meaning a regulatory decision is expected on an expedited timeline. Currently approved pharmacological options for Tourette syndrome are limited to older antipsychotics, including haloperidol and pimozide, and aripiprazole, none of which were developed specifically for the indication. The absence of a purpose-built therapy has left a gap that several companies have attempted to fill, though ecopipam is at present the furthest advanced candidate with a D1-selective mechanism.

The broader movement disorders pipeline is active. Several companies are investigating vesicular monoamine transporter 2 inhibitors and other dopaminergic agents for tic disorders, but none are positioned as direct competitors at the same regulatory stage. For Teva, ecopipam represents a meaningful near-term commercial opportunity within its stated pivot toward innovative medicines, sitting alongside its CGRP franchise in the neurological portfolio. Approval would mark the company's first wholly novel mechanism in the central nervous system in some years.